1994
Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine
Altemus M, Swedo S, Leonard H, Richter D, Rubinow D, Potter W, Rapoport J. Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine. JAMA Psychiatry 1994, 51: 794-803. PMID: 7524463, DOI: 10.1001/archpsyc.1994.03950100042004.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing hormoneLong-term treatmentObsessive-compulsive disorderCSF levelsHomovanillic acidCSF monoamine metabolite levelsCentral administrationCerebrospinal fluid levelsSignificant decreaseCSF homovanillic acidMonoamine metabolite levelsCerebrospinal fluid neurochemistryCSF oxytocin levelsOpposite behavioral effectsPharmacologic treatmentSomatostatin levelsMonoamine metabolitesPathophysiologic processesFluid levelsBehavioral effectsOxytocin levelsClomipramine hydrochlorideMetabolite levelsDisordersVasopressin
1993
Relation of dissociative phenomena to levels of cerebrospinal fluid monoamine metabolites and beta-endorphin in patients with eating disorders: A pilot study
Demitrack M, Putnam F, Rubinow D, Pigott T, Altemus M, Krahn D, Gold P. Relation of dissociative phenomena to levels of cerebrospinal fluid monoamine metabolites and beta-endorphin in patients with eating disorders: A pilot study. Psychiatry Research 1993, 49: 1-10. PMID: 7511247, DOI: 10.1016/0165-1781(93)90026-d.Peer-Reviewed Original ResearchConceptsMonoamine metabolitesCerebrospinal fluid monoamine metabolitesDissociative Experiences ScaleCerebrospinal fluid levelsMajor monoamine metabolitesState-dependent memoryNeurochemical disturbancesAcute phaseOpioid systemNeurochemical changesClinical expressionFluid levelsPatientsPilot studyDisordersNeurobiologic systemsExperiences ScaleMetabolitesDissociative capacityPrevious studiesDopaminergicDissociative phenomenaIllnessCerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers
De Bellis M, Geracioti T, Altemus M, Kling M. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biological Psychiatry 1993, 33: 636-641. PMID: 7687151, DOI: 10.1016/0006-3223(93)90103-k.Peer-Reviewed Original ResearchConceptsMedication-free patientsHealthy volunteersFluoxetine treatmentHomovanillic acidMean Hamilton Depression Rating Scale scoreHamilton Depression Rating Scale scoresDepression Rating Scale scoresPmol/CSF monoamine metabolite levelsFluoxetine-treated patientsCerebrospinal fluid levelsMajor depressive disorderMonoamine metabolite levelsRating Scale scoresCerebrospinal fluid monoamineHVA/5-HIAA ratioCSF HVA/5-HIAA ratioDepressive disorderMajor depressionScale scoreFluid levelsPatientsDSM-IIIMetabolite levelsVolunteers
1992
Abnormalities in the Regulation of Vasopressin and Corticotropin Releasing Factor Secretion in Obsessive-Compulsive Disorder
Altemus M, Pigott T, Kalogeras K, Demitrack M, Dubbert B, Murphy D, Gold P. Abnormalities in the Regulation of Vasopressin and Corticotropin Releasing Factor Secretion in Obsessive-Compulsive Disorder. JAMA Psychiatry 1992, 49: 9-20. PMID: 1370198, DOI: 10.1001/archpsyc.1992.01820010009002.Peer-Reviewed Original Research